Skip to main content

Abstract

Sjögren’s syndrome is a chronic autoimmune disorder of unknown origin. The disease affects mainly the exocrine glands, particularly the salivary and lacrimal glands, resulting in dry mouth and eyes. In more than a half of patients, it extends beyond the exocrine glands affecting parenchymal organs and small-size arteries producing extraglandular manifestation. The disease is common, affecting around 0.5 % of the general population, ranking in second incidence among the systemic autoimmune disorders, after rheumatoid arthritis. The last years’ several clinical and molecular information demonstrated the central role of the epithelial cell in the pathogenesis and clinical expression of the disease and coined the etiologic name “autoimmune epithelitis” for the syndrome.

In the present chapter, the clinical picture with emphasis to skin involvement, recent pathogenetic aspects, and treatment modalities are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Suggested Reading

  • Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34:400–7.

    Article  CAS  Google Scholar 

  • Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM. Prevalence of Sjögren’s syndrome in a closed rural community. Ann Rheum Dis. 1997;56:521–5.

    Article  CAS  Google Scholar 

  • Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A. 2012;109:17609–14.

    Article  CAS  Google Scholar 

  • Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev. 2010;9:A305–10.

    Article  Google Scholar 

  • Moutsopoulos HM. Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol. 1994;72:162–5.

    Article  CAS  Google Scholar 

  • Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, Tzioufas AG, Moutsopoulos HM, Dalakas MC. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82:798–802.

    Article  Google Scholar 

  • Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2012;8:399–411.

    Article  CAS  Google Scholar 

  • Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum. 2000;29(5):296–304.

    Article  CAS  Google Scholar 

  • Triantafyllopoulou A, Moutsopoulos H. Persistent viral infection in primary Sjogren’s syndrome: review and perspectives. Clin Rev Allergy Immunol. 2007;32:210–4.

    Article  CAS  Google Scholar 

  • Tzioufas AG, Moutsopoulos HM. Ultrasonography of salivary glands: an evolving approach for the diagnosis of Sjögren’s syndrome. Nat Clin Pract Rheumatol. 2008;4:454–5.

    Article  Google Scholar 

  • Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjögren’s syndrome: what we know and what we should learn. J Autoimmun. 2012;39(1–2):4–8.

    Article  CAS  Google Scholar 

  • Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjögren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033–7.

    Article  CAS  Google Scholar 

  • Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sjögren’s syndrome. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S66–71.

    CAS  PubMed  Google Scholar 

  • Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore). 2012;91:1–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Athanasios G. Tzioufas .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tzioufas, A.G., Moutsopoulos, H.M. (2015). Sjögren’s Syndrome. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_89

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45139-7_89

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45138-0

  • Online ISBN: 978-3-662-45139-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics